1. Home
  2. ANAB vs ODP Comparison

ANAB vs ODP Comparison

Compare ANAB & ODP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • ODP
  • Stock Information
  • Founded
  • ANAB 2005
  • ODP 1986
  • Country
  • ANAB United States
  • ODP United States
  • Employees
  • ANAB N/A
  • ODP N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • ODP Other Specialty Stores
  • Sector
  • ANAB Health Care
  • ODP Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • ODP Nasdaq
  • Market Cap
  • ANAB 621.1M
  • ODP 546.9M
  • IPO Year
  • ANAB 2017
  • ODP N/A
  • Fundamental
  • Price
  • ANAB $20.14
  • ODP $21.08
  • Analyst Decision
  • ANAB Buy
  • ODP Hold
  • Analyst Count
  • ANAB 10
  • ODP 1
  • Target Price
  • ANAB $48.00
  • ODP $19.00
  • AVG Volume (30 Days)
  • ANAB 500.2K
  • ODP 523.0K
  • Earning Date
  • ANAB 08-06-2025
  • ODP 08-06-2025
  • Dividend Yield
  • ANAB N/A
  • ODP N/A
  • EPS Growth
  • ANAB N/A
  • ODP N/A
  • EPS
  • ANAB N/A
  • ODP 0.84
  • Revenue
  • ANAB $123,164,000.00
  • ODP $6,690,000,000.00
  • Revenue This Year
  • ANAB N/A
  • ODP N/A
  • Revenue Next Year
  • ANAB $24.39
  • ODP N/A
  • P/E Ratio
  • ANAB N/A
  • ODP $25.12
  • Revenue Growth
  • ANAB 304.17
  • ODP N/A
  • 52 Week Low
  • ANAB $12.21
  • ODP $11.85
  • 52 Week High
  • ANAB $40.70
  • ODP $32.21
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 31.39
  • ODP 63.43
  • Support Level
  • ANAB $19.55
  • ODP $17.90
  • Resistance Level
  • ANAB $22.03
  • ODP $19.86
  • Average True Range (ATR)
  • ANAB 1.50
  • ODP 1.24
  • MACD
  • ANAB -0.53
  • ODP 0.28
  • Stochastic Oscillator
  • ANAB 12.05
  • ODP 86.45

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About ODP The ODP Corporation

The ODP Corp operates an integrated B2B distribution platform with divisions focusing on various sectors: ODP Business Solutions serves small to enterprise-level companies with office supplies, technology, furniture, and services. Office Depot Division caters to retail consumers and small businesses through retail locations and eCommerce platforms, offering office supplies, technology, and business services. Veyer Division specializes in supply chain, distribution, and procurement services for both internal and third-party customers, with a focus on international operations. Varis Division offers a tech-enabled B2B indirect procurement marketplace, providing a seamless buying experience and advanced spend management tools. Revenue stems from the Veyer division.

Share on Social Networks: